Novo Nordisk Marches Beyond Obesity as Hemophilia Data and Buyback Bolster Confidence
Novo Nordisk’s B-shares closed at €43.32 on Friday, adding 1.29% as the stock continues its recovery from a…
Novo Nordisk Maps Out a Future Beyond Weight Loss, but Investors Are Counting the Days to 2027
Novo Nordisk unveils longevity and aesthetics strategy at ADA, but stock languishes as CagriSema approval not expected until…
Novo Nordisk’s European Breakthrough Tempered by Growing Generics Threat in Brazil and Beyond
France will publicly reimburse Wegovy and Mounjaro, and EMA backs new oral and high-dose versions, but Brazil’s first…
Novo Nordisk’s Sickle Cell Success Charts a New Path Beyond Blockbuster Drugs
Novo Nordisk’s etavopivat reduces sickle cell crises by 27% in Phase 3 trial, marking a key diversification move…
Novo Nordisk’s Sickle Cell Success Charts a New Path Beyond Blockbuster Drugs
Novo Nordisk’s etavopivat reduces sickle cell crises by 27% in Phase 3 trial, marking a key diversification move…
Novo Nordisk Seeks Growth Beyond Flagship Drugs with New Obesity Pill Trial
Novo Nordisk starts Phase 1 trial for oral obesity drug LX9851, a strategic move to diversify beyond GLP-1…